Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer

Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer

Background and objective Programmed cell death 1 or programmed cell death ligand 1 inhibitor (PD-1/PD-L1 inhibitor) and docetaxel, as the standard second-line treatments of advanced non-small cell lung cancer (NSCLC) patients, have limited effects. There are few studies on whether docetaxel combined...

Full description

Bibliographic Details
Main Authors: Qing CHEN, Yan LI, Wenjie ZHANG, Shengjie YANG, Chen WANG, Qisen GUO, Wenna SHI
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-09-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
docetaxel
pd-1/pd-l1 inhibitor
safety
efficacy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.26

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.26

Similar Items